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Abstract
Background: Amyotrophic Lateral Sclerosis (ALS) is neurodegenerative disease characterized by muscle weakness and
atrophy due to progressive motoneuron loss. The death of motoneuron is preceded by the failure of neuromuscular
junctions (NMJs) and axonal retraction. Thus, to develop an effective ALS therapy you must simultaneously preserve
motoneuron somas, motor axons and NMJs. A conditioning lesion has the potential to accomplish this since it has been
shown to enhance neuronal survival and recovery from trauma in a variety of contexts.
Methodology/Principal Findings: To test the effects of a conditioning lesion in a model of familial ALS we administered a
tibial nerve crush injury to presymptomatic fALS
G93A rats. We examined its effects on motor function, motoneuron somas,
motor axons, and NMJs. Our experiments revealed a novel paradigm for the conditioning lesion effect. Specifically we found
that the motor functional decline in fALS
G93A rats that received a conditioning lesion was delayed and less severe. These
improvements in motor function corresponded to greater motoneuron survival, reduced motor axonopathy, and enhanced
NMJ maintenance at disease end-stage. Furthermore, the increased NMJ maintenance was selective for muscle
compartments innervated by the most resilient (slow) motoneuron subtypes, but was absent in muscle compartments
innervated by the most vulnerable (fast fatigable) motoneuron subtypes.
Conclusions/Significance: These findings support the development of strategies aimed at mimicking the conditioning
lesion effect to treat ALS as well as underlined the importance of considering the heterogeneity of motoneuron sub-types
when evaluating prospective ALS therapeutics.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive neurode-
generative disease characterized by the loss of motoneurons. The
majority of ALS cases are sporadic in origin (,90%), and the
remaining 10% of cases are the inherited form, commonly referred
to as familial (f)ALS [1]. For more than a decade Riluzole has
remained the only medication proven to slow, albeit very
modestly, the progression of ALS. This lack of success in ALS
therapeutic development has not been due to lack of effort. Rather
it seems to be reflective of our incomplete understanding of disease
mechanisms. For example, only recently has it become widely
accepted that maintaining motor axons and neuromuscular
junctions (NMJs) are distinct from, but no less important than
preventing motoneuron cell death in ALS [2]. Thus, developing
therapies aimed at preserving both motoneurons and their
connections with muscle should be prioritized.
Conditioning lesions have been shown to augment neuronal
survival and recovery following a subsequent injury. In the PNS,
conditioning lesions have been shown to enhance regeneration
rate [3,4] and the extent of axon collateral sprouting [5,6]. If
dorsal root crush injury is preceded by a peripheral nerve axotomy
the ability for regenerating axons of the central process to
overcome inhibitory growth cues is increased [7,8,9]. Additionally,
sub-lethal insults to basal forebrain neurons have been shown to
confer neuroprotection [10]. Therefore the present study set out to
study the effects of a conditioning lesion applied to presymptom-
atic fALS
G93A rats on the preservation of motor function,
motoneurons, motor axons and NMJs.
Results
Conditioning lesion focally reduced motor functional
decline
To determine the effects of a conditioning lesion on disease
progression in fALS
G93A rats we crushed the tibial nerve at age 10
weeks (wk). We considered this a conditioning lesion because it was
administered prior to the onset of both motoneuron loss occurs
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nerve crush the function of the ankle extensor muscles was severely
compromised and behavioral recovery took 3–4 wk (Figure 1A–C).
The relatively large decreases in hindlimb grip strength (GS;
276.865.9%) and BBBlocomotor rating (243.368.1%) 1 wkafter
nerve injury indicated these tests were highly sensitive to tibial nerve
function. In contrast, nerve injury had lesser or no effects on ALS
motor score (220.060.0%) and body weight (+1.361.1%)
respectively, which was consistent with the more holistic nature of
thesetests.From ages 15–18 wk,all behavioral testsproducedstable
results in both groups. At 19 wk, hindlimb GS was significantly
reduced in Sham (75.7613.3%) versus Crush (101.566.2%;
p=0.028). At 20 wk, both hindlimb GS (55.066.2% vs.
85.468.0%; p=0.011) and BBB score (12.163.0 vs. 17.861.7;
p=0.013) were decreased in Sham versus Crush. In contrast, the
ALS motor score, which provides a more holistic view of motor
function [11], did not vary significantly between groups at any time
beyond age 12 wk. From age 20 wk onward all behavioral tests
revealed a progressive decline in both groups. Body weight was
similar between groups except at age 22 wk (p=0.026), but this
differencewas likely an anomalycausedby the coincidental death of
3 Sham group animals between ages 22–23 wk (Figure 1D). In
support of this interpretation, end-stage body weight for Crush and
Sham were not statistically different (74.462.8% vs. 78.562.3%;
p=0.196). However, when motor function was compared at end-
stage the Crush group outperformed Sham in hindlimb GS
(38.468.8% vs. 16.661.9%; p=0.012) and BBB (2.061.1 vs.
0.3660.38; p=0.051). Finally, at end-stage the ability to move the
ankle joint extensively remained more frequently in Crush (5/9 or
56%) than in Sham (1/9 or 11%) rats.
Disease onset, duration and survival were not altered
The behavioral benefits of a conditioning lesion in fALS
G93A
rats were focal (Figure 1A–B) rather than holistic (Figure 1C–D).
Whether the focal preservation of ankle extensor function could
alter disease progression seemed doubtful. To confirm this we
compared disease onset, duration and survival between Crush
(n=9) and Sham (n=9). Disease onset was defined objectively as
the point where maximum body weight was reached and did not
vary with Sham (17.960.5 wk) or Crush (18.360.5 wk). Further-
more, neither disease duration (4.760.7 wk vs. 4.760.5 wk) nor
survival (22.660.7 wk vs. 22.960.8 wk) differed between Sham
and Crush respectively (Figure 2).
Conditioning lesion decreased motoneuron loss
In fALS
G93A rodents, there are conflicting reports as to whether
a previous nerve injury increases [12,13,14] or decreases [15] the
vulnerability of motoneurons. We explored this issue by
comparing the density of L4–6 motoneurons at end-stage of
Crush and Sham fALS
G93A rats. Relative to 10 wk (pre-operative
age), motoneurons at end-stage in Crush seem better preserved
than in Sham (Figure 3A–C). The motoneuron density for 10 wk
controls (22.661.6) had a tendency to be greater than end-stage
Crush (15.362.7; p=0.058). However, both 10 wk (p,0.01) and
Crush (p,0.05) had significantly greater density than either Sham
(7.561.3) or the unoperated side (i.e. Contra) of Crush (8.361.6).
Consistent with the significant protection of motoneurons, we saw
clear differences in the number of myelinated axons in 10 wk
(n=4), Crush (n=4) and Sham (n=4) L4 ventral roots (VRs;
Figure 4A–C).
It is recognized that larger motoneurons are more susceptible to
atrophy and/or death in ALS [16,17,18]. So we considered the
affects of axotomy on the size of the remaining motoneurons
(Figure 3E). We found 10 wk (676.3663.6 mm
2) motoneurons
Figure 1. Conditioning lesion reduces the decline of motor
function. (A) The mean (6 SE) hindlimb grip strength for Crush (grey
circles) and Sham (black circles). (B) The mean (6 SE) BBB locomotor
score relative for Crush and Sham. (C) The mean (6 SE) ALS motor score
for Crush and Sham. (D) The mean (6 SE) body weight for Crush and
Sham. The number of animal assessed in each group over time is
indicated at the bottom of graph D. #, P,0.01; *, P,0.05.
doi:10.1371/journal.pone.0007357.g001
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(503.6640.5 mm
2), Sham (470.5624.1 mm
2) and Contra Crush
(483.1615.2 mm
2). Interestingly, histogram analysis of motoneu-
ron areas revealed that while sizes for Crush (n=276 cells/6 rats)
were shifted towards smaller values relative to 10 wk (n=195
cells/4 rats), when compared to either Sham (n=107 cells/6 rats)
or Contra Crush (n=164 cells/6 rats) noticeably more large cells
(.1000 mm) remained in Crush (Figure 3F–I). Similarly, quanti-
fication of L4 VRs showed that the number of large diameter
(.8 mm) axons was significantly reduced for Sham (229.3670.3)
as compared to Crush (537.76133.5; p,0.05) and 10 wk
(871.5647.6; p,0.01), but there was no difference in the number
of small diameter (,8 mm) axons between groups (Figure 4D).
Taken together this indicates that Crush treatment prevents the
loss and/or atrophy of at least some larger motoneurons.
Conditioning lesion selectively preserved resilient NMJs
The death of motoneurons in ALS is preceded by the loss of
NMJs and axonopathy. Recently it has been shown that NMJs are
more severely compromised in fast versus slow muscle fibers of
fALS
G93A mice [19,20]. The extent to which a conditioning lesion
affects innervation at end-stage in distinct compartments of the
fALS
G93A rat MG containing either mixed (,50% fast/50% slow)
or only fast fibers was examined with immunohistochemistry
(Figure 5A–C). In the mixed region, the percentage of innervated
NMJs was greater for Crush (44.166.9%, n=532 NMJs/6 rats)
than Sham (17.961.9%, n=618 NMJs/6 rats, p,0.01), but
compared to 10 wk (95.861.6%, n=366 NMJs/4 rats, p,0.01)
both were less (Figure 5D). In the fast region, the percentage of
innervated NMJs was not different between Crush (10.962.7%,
n=182 NMJs/6 rats) and Sham (6.061.9%, n=217 NMJs/6 rats;
p=0.168), but compared to 10 wk (70.4613.6%, n=98 NMJs/4
rats, p,0.01) both were less (Figure 5E). The percentage of
innervated NMJs was not different between the fast and slow
regions at 10 wk (p=0.160), but did differ at end-stage for both
Crush (p,0.01) and Sham (p,0.01).
Discussion
We have shown that a conditioning lesion in fALS
G93A rats
reduced motor functional decline, motoneuron loss, axonopathy,
and muscle denervation in a focal manner. In addition, the
conditioning lesion-induced enhancement of protection appeared
to be exclusive for already ALS-resistant motoneuron subtypes.
This represents a significant advance from previous studies of
nerve injuries in fALS
G93A rodents, which either didn’t allow
muscle reinnervation to occur [13,14,15] and/or only studied their
effects at intermediate stages of disease progression [12,13,14,21].
Overall, our findings describe a novel paradigm for the
conditioning lesion effect as well as imply that strategies aimed
at mimicking this effect could be effective ALS therapies.
Nerve Injuries and fALS
It seems counter-intuitive that a nerve injury could improve the
maintenance of motor function and neuroprotection in a model of
fALS. Axotomy itself can threaten the survival of motoneurons
depending on age, motoneuron type, and nature of the lesion [22].
Complete recovery of function after peripheral nerve injury is
rarely achieved [23]. In addition, the processes of axon
regeneration and synaptogenesis place metabolic burden on
already vulnerable cells. However, past research exploring the
effects of nerve injury in fALS
G93A rodents have reported both
protective [15] and detrimental [12,13,14] effects on motoneuron
survival. For example, following sciatic nerve injury Kong and Xu
found 33% more VR axons at end-stage [15], but later studies that
examined sciatic [12] or facial[13,14] nerve injury found 5–47%
fewer motoneurons at disease onset.
The reason for these discrepancies is likely multifactorial. First, the
age of injury must be considered because ALS involves progressive
neurodegeneration. The aforementioned studies, plus our own
administered nerve injury to fALS
G93A rodents ranging from ages
6–10 wk, which corresponds to a disease phase just after the onset of
axonopathy but prior to the lossof motoneurons or physical symptom
Figure 2. Conditioning lesion does not alter disease onset,
survival or duration. (A) The onset of disease was similar for Crush
(grey broken line) and Sham (black line) groups. (B) The age of death
was not changed by the conditioning lesion. (C) The duration of the
disease did not differ between groups.
doi:10.1371/journal.pone.0007357.g002
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seem insufficient to account for these widely discrepant results.
Second, due to their greater dependence on target-derived trophic
support, adult cranial motoneurons are much more susceptible to
axotomy-induced cell death than adult spinal motoneurons [22].
Hence, survival of adult facial and sciatic motoneurons following
Figure 3. Conditioning lesion protects motor neurons at end-stage. (A–C) Representative examples of Nissl stained ventral horns from the
L4–6 spinal cord of 10 wk un-operated, Crush, and Sham. (D) The mean (6 SE) density of motor neurons per section compared between 10 wk,
Crush, Sham and the contralateral side of Crush (Contra). (E) The mean (6 SE) area of motor neuron somas shown for each group. (F–I) Histograms
show the distribution of motor neuron areas for each group. Scale bar represents 250 mm. #, P,0.01; *, P,0.05.
doi:10.1371/journal.pone.0007357.g003
Conditioning Lesion for ALS
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nerve injury (e.g. ligation vs. crush) either prevented or allowed
muscle reinnervation. As expected, motor function was permanently
impaired when muscle reinnervation was prevented by nerve ligation
[15]. In contrast, muscle was more fatigue-resistant [12] and motor
function was better maintained (Figure 1) when muscle reinnervation
was allowed after nerve crush. Finally, the effects of axotomy were
assessed at different phases of the disease. At disease onset, the
survival of axotomized motoneurons was diminished [12], but at end-
stage, survival of axotomized motoneurons was enhanced [15]
(Figure 3). Therefore it appears that axotomy has opposing effects on
motoneuron survival depending on what disease phase is used as the
experimental end point.
To better account for these opposing effects we explored the
heterogeneity of motoneuron loss in ALS [24]. Although ALS is
Figure 4. Conditioning lesion preserves ventral root axons at
end-stage. (A–C) Photomicrographs of L4 VRs stained with toluidine
blue and taken at either 20 or 100X. (D) The mean (6 SE) number of
large (black bars; .8 mm) and small (white bars; #8 mm) myelinated
axons. Scale bar represents 150 mm (20X) or 25 mm (100X). #, P,0.01;
*, P,0.05.
doi:10.1371/journal.pone.0007357.g004
Figure 5. Conditioning lesion selectively preserves NMJs at
end-stage. (A–B) Motor endplates were stained with a-bungarotoxin
(red); axons were stained with antibodies for synaptophysin and class III
b-tubulin (green). (C) A diagram depicting MG muscle compartments
containing mixed (fast & slow) or only fast muscle fibers. (D–E) The
mean (6SE) percentage of innervated NMJs was quantified for the
mixed and fast muscle compartments of the MG muscle from 10 wk,
Crush, and Sham. Scale bar represents 50 mm (A, B) or 1 mm (C). #,
P,0.01; *, P,0.05.
doi:10.1371/journal.pone.0007357.g005
Conditioning Lesion for ALS
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afflicted equally. For example, evidence from both ALS patients
and animal models suggest that motoneurons innervating the
greatest numbers of muscle fibers are compromised earliest
[25,26,27]. It has also been reported that motoneurons with the
largest somas and axons are more likely to be lost and/or become
atrophic [16,17,18]. These observations are congruent, since
bigger motoneurons generally innervate more muscle fibers [28],
and support the popular hypothesis that motoneurons are
specifically lost in ALS due to the burden of maintaining large
somas, long axons, and multiple synaptic connections with muscle
fibers. Elegant studies by Kong and Xu provided strong
experimental evidence for this hypothesis and suggested that a
size threshold might determine motoneuron survival. Specifically,
they found that chronic axotomy caused axonal atrophy in wild-
type mice, protected VR axons in fALS
G93A mice, and increased
the proportion of small diameter axons in fALS
G93A mice [15,17].
However, evidence against a direct relationship between smaller
size and ALS-resistance includes the absence of protection when
axon caliber was genetically reduced in fALS
G37R mice [29], and
our findings that the axotomy-induced protection in fALS mice
was not exclusive to motoneurons with small somas (Figure 3) and
axons (Figure 4).
Since motoneuron size does not fully explain the effects of
axotomy we considered motoneurons in terms of function.
Corresponding to the muscle fiber type it exclusively innervates
(Type I or II) a motoneuron can functionally defined as slow (S) or
fast (F) respectively. F motoneurons can be further described as
fatigable (Fff; Type IIb), intermediate (Ffi; Type IIx), and fatigue-
resistant (Ffr; Type IIa). Along with well described differences in
contraction speed, strength and fatigability of their muscle
fibers[23], these motoneuron subtypes differ in their vulnerability
to degeneration in fALS
G93A mice [19,20,21,26] and rats
(Figure 5). The most susceptible are F motoneurons (Fff.Ffi,fr),
which withdraw much of their innervation pre-symptomatically,
and the most resilient are S motoneurons, which do not begin to
display signs of axon degeneration until approximately disease
onset [21]. Not only is this consistent with the hypothesis that
bigger motoneurons are more susceptible in ALS, since F
motoneurons are generally larger and innervate more muscle
fibers then S motoneurons [28], but it may also accounts for the
absence of a simple relationship between size and vulnerability
[29] (Figures 3 and 4), since the range of sizes for S and F
motoneurons are known to overlap considerably [30]. Further-
more, strong evidence exists that the axotomy-induced protection
in fALS
G93A rodents was selective for S motoneurons because
reinnervated muscle became more fatigue-resistant [12], had
greater oxidative capacity [12], and maintained more NMJs
exclusively in sub-compartments with S innervation (Figure 5).
Although far from conclusive, there is also evidence to suggest that
axotomy may have the opposite effect on the most vulnerable (i.e.
Fff) motoneurons. For example, when the sciatic nerve of
fALS
G93A mice was crushed at age 5.5wk (i.e. .1.5 wk prior to
the earliest disease-related denervation), reinnervation deficits
were found 1 wk later selectively in muscle compartments that had
Fff innervation [21]. However, it is not known whether this
observation represented an axotomy-induced acceleration of Fff
motoneuron degeneration and/or impairment of Fff axon
regeneration.
Making medicine from mechanism
While understanding the mechanisms underlying the selective
loss of motoneurons remains one of the greatest challenges in ALS
research, exploiting the known mechanisms that confer resiliency
to specific motoneuron subtypes provides a great opportunity to
develop new therapies. For reasons that are poorly understood,
functional subtypes of motoneurons have distinct vulnerabilities
in ALS [24]. Greater resiliency is found in motoneurons that
have smaller axons, lesser innervation ratios, and synapse with
muscle fibers that are slow contracting and more oxidative
[19,20,21,26,27]. Pre-symptomatic nerve injury in fALS
G93A
rodents (i.e. conditioning lesion) selectively increases the resiliency
of motoneurons possessing some or all of these characteristics
[12,15] (Figures 3–5). Taken together this highlights the relevance
to ALS of exploring: (i) the factors underlying the growth and
survival of specific motoneuron types; and (ii) strategies to
transform motoneurons from vulnerable (e.g. Fff) to resilient
(e.g. S) phenotype.
Regarding the first point, peripheral nerve axotomy is known to
cause the upregulation of various neurotrophic factor (NFs) and
their receptors [31]. NF-based therapies have been among the
most effective therapeutic approaches tested in preclinical models
of ALS [32], and could conceivably underlie the effects seen in the
present study. It is well established that different classes of neurons
are responsive to different NFs or combinations of NFs. Even
within classes of neurons, such as motoneurons, there exists
considerably heterogeneity in responsiveness to specific NFs [33].
For example, the application of Neurotrophin-3 (NT-3) to
regenerating axons appears to selectively augment the regenera-
tion of Fff motoneurons [34,35] because of their relatively high
expression of its corresponding tyrosine kinase receptor, trkC [36],
whereas NT-4 appears to selectively augment the regeneration of
S motoneurons [37] probably because they express relatively more
of the trkB receptor [38]. However, the extensive intermingling of
F and S motoneurons in the spinal cord, combined with absence of
distinguishing molecular markers, have hampered efforts to
explore the molecular heterogeneity of F and S motoneurons
more definitively. Future studies directed towards increasing our
knowledge of the variability between motoneuron subtypes might
be leveraged to optimize the impact of growth factors, which,
while promising [39], have so far failed to translate into ALS
therapies.
Regarding the second point, progress should be more rapid
given that the transformation of F motoneurons towards the S
phenotype can be accomplished with chronic electrical stimulation
and to a lesser extent exercise [40,41]. Although chronic electrical
stimulation has not yet been studied in an ALS model, different
exercise regimes have been shown to modestly extend life in
fALS
G93A mice [42,43,44]. It remains to be determined to what
extent, if any, the conversion of motoneurons to more resilient
subtypes (e.g. S.FFfi,fr.Fff) may have contributed to this exercise-
induced protection. Clinical investigations of varying exercise
regimes in ALS patients have been shown to both lessen disease
symptoms and improved function [45,46,47], nevertheless there
remains some concern among clinicians about advocating exercise
to ALS patients because of the conflicting epidemiological reports
on whether physical activity may [48,49,50,51] or may not
[52,53,54] be a disease risk factor.
Materials and Methods
Rats
Experiments were performed on fALS
G93A rats, which were
transgenically engineered to express the human Cu
+2/Zn
+2
superoxide dismutase 1 gene with a glycine to alanine base pair
mutation at its 93
rd codon [55]. The founders for the fALS
G93A
colony were obtained from Taconic Farms (Germantown, NY)
and bred locally. Genotyping was performed by PCR as previously
Conditioning Lesion for ALS
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Animal Care and Use Committee of Emory University.
Surgery
All surgeries were performed on 10 wk old fALS
G93A rats.
While anesthetized with 2% isoflurane, an incision was made
parallel to and below the femur, and the tibial nerve was exposed.
In the Crush group (n=9), the tibial nerve was crushed with
jeweler’s forceps for 10 sec at the level of the knee. The crush site
was visually inspected to confirm that all axons were severed as
indicated by a translucent appearance. In the Sham group (n=9),
following a 10 sec exposure of the tibial nerve, the wound was
closed with the nerve intact. To control for gender or generational
differences the Crush and Sham groups were balanced with
littermates of both sexes.
Behavioral Analysis
Baseline motor behavioral tests were performed by a blinded
tester 1–3 days prior to surgery, and then post-operatively 1 x/wk
until end-stage, which was defined as the day at which they were
unable to right themselves within 30 sec of being placed on either
side [55]. Motor behavioral measurements included hindlimb grip
strength (GS), Basso-Beatti-Bresnahan (BBB) locomotor rating
[57], and ALS motor score [11]. The GS measurements were
made with an automated GS meter (Columbus Instruments,
Columbus, OH) with the average of 3–6 trials recorded. Disease
onset was defined retrospectively as the day when rats reached
their maximum body weight.
Neuropathology
Post-operatively fALS
G93A rats were perfused with 4% parafor-
maldehyde (PFA) at end-stage. To serve as pre-operative controls
several fALS
G93A rats were perfused at age 10 wk (n=4). Tissues
were processed for assessment of motoneurons, ventral root (VR)
axons, and NMJs.
Motoneurons
A segment of the spinal cord was isolated from L3-S1. It was
cryoprotected in 30% sucrose until sinking, immersed in OCT, flash
frozen indryice cooled isopentane, and cryostat sectioned on to slides
at 20 mm. The tissue was air dried overnight, stained with cresyl
violet, and mounted with Permount (SP15-100, Fisher Scientific, Fair
Lawn, NJ). Every 18th section (i.e. 360 mmi n t e r v a l ;6 – 8s e c t i o n s / r a t )
was imaged from the L4–6 spinal cord. Images were acquired at 20X
magnification using a Nikon DS-Fi1 color digital camera on a Nikon
E400 microscope and analyzed using the NIS-Elements software
(Nikon Instruments Inc, Melville, NY). All Nissl-stained neurons in
the ventral horn that had a distinct nucleus were manually traced to
determine area. Conservatively, ventral horn neurons with areas
$300 mm were counted as motoneurons [56].
Ventral Roots
A 3–4 mm segment of the right L4 VR was dissected from the
spinal cord, post-fixed in 4% PFA, treated with 1% tetroxide for
90 min, dehydrated through graded alcohols, and embedded in
Epon plastic (EM Sciences, Cincinnati, OH). Cross-sections
(720 nm) were stained with toluidine blue, rinsed, and mounted
with Permount (Fisher Scientific). Images were acquired as
described above for motoneurons except the magnification used
was 100X. Myelinated axons were measured using NIS-element
software.
Neuromuscular Junctions
The medial gastrocnemius (MG) muscle was isolated from the
right leg, immersed in 20% sucrose mixed with OCT (1:2), flash
frozen in dry ice-cooled isopentane, and the mid-belly of its
proximal compartment was cryostat sectioned on to slides at
20 mm. The tissue was air dried overnight, blocked for 1 hr at
room temperature in PBS containing 0.3% triton x-100 and 2.5%
bovine serum albumin (BSA), incubated overnight at 4uC in rabbit
anti-neuronal class III b-tubulin (1:1000; PRB-435P, Covance,
Emeryville, CA) and rabbit anti-synaptophysin (1:100; Invitrogen,
Carlsbad, CA) diluted in blocking solution, washed several times
with PBS, incubated overnight at 4uC in goat anti rabbit IgG
secondary antibody conjugated to Alexa Fluoro 488 (1:500;
Invitrogen) and rhodamine conjugated a-bungarotoxin (1:100;
Invitrogen) diluted in blocking solution, washed several times in
PBS, and then mounted in glycerol-PBS (1:1) mixture. Images
were acquired as described above for motoneurons. The
percentage of innervated NMJs was determined based on the
co-localization of the pre-synaptic (class III b-tubulin and
synaptophysin) and post-synaptic (a-bungarotoxin) markers.
Statistics
Mean values (6 standard error of the mean; SE) are shown
throughout. The student’s t-test was used to make comparisons
between time-matched Crush and Sham data. The Kaplan-Meier
curves were generated with Sigmaplot software (Systat Software,
Chicago, IL). One-way ANOVAs were used to make comparisons
for the motoneuron and NMJ quantifications. If the F-critical
value was exceeded, Tukey’s Honestly Significant Difference post
hoc test was then applied.
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